TP53 and lung carcinoma: Breast and lung cancer patients with elevated expression of MDM2 in concert with alterations in TP53 (mut TP53/high MDM2) exhibit lower survival rate post chemotherapy with respect to patients that possessed mutations in TP53 or overexpressed MDM2 independently (Figure 1).